← back to search

Samuel W. Brady

St. Jude Children's Research Hospital · US
Area of research
Cancer Research · Public Health, Environmental and Occupational Health
Research interest
Research interests include Cancer Genomics and Diagnostics, Acute Lymphoblastic Leukemia research, Genomics and Rare Diseases, and RNA modifications and cancer.
h-index
27
citations
3,701
works
205
NIH funding
primary concept
email

Recent publications

The genomic landscape of pediatric acute lymphoblastic leukemia
Nature Genetics 2022cited by 383position: firstdoi
Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor
Cell Genomics 2022cited by 356position: middledoi
Enhancer retargeting of <i>CDX2</i> and <i>UBTF::ATXN7L3</i> define a subtype of high-risk B-progenitor acute lymphoblastic leukemia
Blood 2022cited by 49position: middledoi
Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed Therapy
Blood Cancer Discovery 2021cited by 150position: middledoi
The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma
Nature Communications 2021cited by 90position: middledoi
Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse
Nature Cancer 2021cited by 49position: middledoi
The landscape of coding RNA editing events in pediatric cancer
BMC Cancer 2021cited by 24position: middledoi
Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia
Blood 2019cited by 299position: middledoi
Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer
Nature Communications 2019cited by 194position: middledoi
Engineered 3D Model of Cancer Stem Cell Enrichment and Chemoresistance
Neoplasia 2019cited by 58position: middledoi
The Small GTPase ARF6 Activates PI3K in Melanoma to Induce a Prometastatic State
Cancer Research 2019cited by 31position: middledoi
Combating subclonal evolution of resistant cancer phenotypes
Nature Communications 2017cited by 176position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Andrea H. Bild · City Of Hope National Medical Center3 papers (2019–2019)Charles G. Mullighan · Dana-Farber Cancer Institute2 papers (2021–2021)Tanja A. Grüber · Palo Alto University2 papers (2021–2021)David A. Kircher · University of Utah1 papers (2019–2019)Donghan Shin · University of California, Irvine1 papers (2019–2019)Ronald J. Buckanovich · University of Michigan–Ann Arbor1 papers (2019–2019)Geeta Mehta · University of Michigan1 papers (2019–2019)Joy Hendley · Peter MacCallum Cancer Centre1 papers (2019–2019)Gregory V. Lamb · University of Pretoria1 papers (2019–2019)Jun J. Yang · Yunnan University of Traditional Chinese Medicine1 papers (2021–2021)Sián Fereday · The University of Melbourne1 papers (2019–2019)Jingfu Peng · University of Utah1 papers (2019–2019) · 1 papers (2019–2019)Roger K. Wolff · University of Utah1 papers (2019–2019)Sheri L. Holmen · University of Utah1 papers (2019–2019)Jessica A. Beach · Peter MacCallum Cancer Centre1 papers (2019–2019)Dario Campana · National University of Singapore1 papers (2021–2021)Jeffrey E. Rubnitz · Children's Hospital1 papers (2021–2021)Aaron Rogers · University of Utah1 papers (2019–2019)Coulson P. Rich · Huntsman Cancer Institute1 papers (2019–2019)